Posted 15th May 2019 by Joshua Broomfield
The first topic I worked on that combined Blockchain and healthcare was the project I’m going to talk about at the Blockchain in Healthcare Congress. It was commissioned by the Finnish government, looking at how blockchain technology and Smart Contracts could help in a planned governmental social and healthcare reform.
Posted 1st May 2019 by Joshua Broomfield
Blockchain technology is still in its nascency in the healthcare industry. At Frost & Sullivan, we do research and consulting for leading pharmaceutical and diagnostic companies, and the digital solution vendors that are providing Blockchain solutions to end-users.
Posted 26th April 2019 by Joshua Broomfield
Alongside my primary role as a Project Manager, I have since 2016 been the Roche lead for the IMI industry collaboration called EHR4CR. EHR4CR is a group of roughly 10 pharma companies, universities, and SMEs working together to leverage the great wealth of information from hospitals in order to support our clinical trials and promote innovative research. It was a 7-year $16 million project.
Posted 17th December 2018 by Jane Williams
As industry developments continue to improve, the potential for personalised medicine and the possibility of individual diagnosis is on the horizon. These slides, from the Precision Medicine & Biomarkers Leaders Summit: Europe are now available from Andres Hurtado-Lorenzo, Thorsten Gutjahr & Thomas Skot Jensen.
Posted 26th September 2018 by Jane Williams
Immunotherapy continues to gain popularity in several areas related to cancer research and new treatments. Studies prove that each and every cancer case is unique, so the need for personalised medicine presents a logical focus. Personalised cancer vaccines are one form of cancer immunotherapy. The vaccines are a form of precision medicine, which has become an increasingly more enticing area for treatment research.
Failing Blockbuster Medicines, Eroding Operator Margins & Increased Pricing Pressures: What’s Next for Precision Medicine?
Posted 12th September 2018 by Jane Williams
The Precision Medicine and Biomarkers Leaders Summit: Europe takes place this week and in anticipation, we spoke to Unmesh Lal of Frost and Sullivan about his views on what the future holds for precision medicine and how the pharmaceutical industry has changed in recent times.
Posted 5th September 2018 by Jane Williams
I don’t need to tell you that pharma has changed, that it is still changing at speed, or that change is the new normal. I don’t need to tell you because you − more than anyone else − already know. The passing of the blockbuster era has caused uncertainty. Without the superstar drugs of old, where does the industry go next? It’s a serious challenge, but without challenge, there is no change. The answer, of course, is the scalar shift from blockbuster generic to precision medicine specific.
Posted 24th August 2018 by Jane Williams
We spoke to Alex Bastian about how he got started in precision medicine, where he sees it going and how he intends to use real world evidence to unlock the potential around personalised approaches to drug development: